Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1992 Dec;107(4):1020–1028. doi: 10.1111/j.1476-5381.1992.tb13401.x

Central administration of 5-HT activates 5-HT1A receptors to cause sympathoexcitation and 5-HT2/5-HT1C receptors to release vasopressin in anaesthetized rats.

I K Anderson 1, G R Martin 1, A G Ramage 1
PMCID: PMC1907911  PMID: 1467825

Abstract

1. The effects of intracerebroventricular injections to the right lateral ventricle (i.c.v.) of 5-hydroxytryptamine (5-HT, 40 and 120 nmol kg-1), N,N-di-n-propyl-5-carboxamidotryptamine (DP-5-CT; 3 nmol kg-1), 5-carboxamidotryptamine (5-CT; 3 nmol kg-1), 8-hydroxy-2-(di-N-propylamino) tetralin (8-OH-DPAT; 3, 40 and 120 nmol kg-1) and 1-(2,5-di-methoxy-4-iodophenyl)-2-aminopropane (DOI; 40 and 120 nmol kg-1) on renal sympathetic nerve activity, blood pressure, heart rate and phrenic nerve activity were investigated in normotensive rats anaesthetized with alpha-chloralose. 2. 5-HT caused a long lasting pressor response which was associated with an initial bradycardia and renal sympathoinhibition followed by a tachycardia and renal sympathoexcitation. Pretreatment with the 5-HT2/5-HT1C receptor antagonists, cinanserin (300 nmol kg-1, i.c.v.) or LY 53857 (300 nmol kg-1, i.c.v.) reversed the initial bradycardia and sympathoinhibition to tachycardia and sympathoexcitation. Combined pretreatment with LY 53857 (300 nmol kg-1, i.c.v.) and the 5-HT1A antagonist, spiroxatrine (300 nmol kg-1, i.c.v.), blocked the effects of 5-HT on all the above variables. 3. Pretreatment with the vasopressin V1-receptor antagonist, beta-mercapto-beta,beta-cyclopentamethylene-propionyl1, O-Me-Tyr2, Arg8-vasopressin [(d(CH2)5Tyr(Me)AVP, 10 micrograms kg-1, i.v.] did not affect the magnitude but reduced the duration of the pressor response produced by i.c.v. 5-HT and reversed the initial bradycardia and renal sympathoinhibition to tachycardia and sympathoexcitation. 4. 1-(2,5-Di-methoxy-4-iodophenyl)-2-aminopropane (DOI) caused a pressor effect which was associated with a bradycardia and sympathoinhibition.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
1020

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alper R. H. Hemodynamic and renin responses to (+-)-DOI, a selective 5-HT2 receptor agonist, in conscious rats. Eur J Pharmacol. 1990 Jan 17;175(3):323–332. doi: 10.1016/0014-2999(90)90571-m. [DOI] [PubMed] [Google Scholar]
  2. Bagdy G., Sved A. F., Murphy D. L., Szemeredi K. Pharmacological characterization of serotonin receptor subtypes involved in vasopressin and plasma renin activity responses to serotonin agonists. Eur J Pharmacol. 1992 Jan 21;210(3):285–289. doi: 10.1016/0014-2999(92)90417-3. [DOI] [PubMed] [Google Scholar]
  3. Bagdy G., Szemeredi K., Murphy D. L. Marked increases in plasma catecholamine concentrations precede hypotension and bradycardia caused by 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) in conscious rats. J Pharm Pharmacol. 1989 Apr;41(4):270–272. doi: 10.1111/j.2042-7158.1989.tb06450.x. [DOI] [PubMed] [Google Scholar]
  4. Brownfield M. S., Greathouse J., Lorens S. A., Armstrong J., Urban J. H., Van de Kar L. D. Neuropharmacological characterization of serotoninergic stimulation of vasopressin secretion in conscious rats. Neuroendocrinology. 1988 Apr;47(4):277–283. doi: 10.1159/000124925. [DOI] [PubMed] [Google Scholar]
  5. Buñag R. D., Miyajima E. Sympathetic hyperactivity elevates blood pressure during acute cerebroventricular infusions of hypertonic salt in rats. J Cardiovasc Pharmacol. 1984 Sep-Oct;6(5):844–851. doi: 10.1097/00005344-198409000-00017. [DOI] [PubMed] [Google Scholar]
  6. Chaouloff F., Baudrie V., Laude D. Evidence that the 5-HT1A receptor agonists buspirone and ipsapirone activate adrenaline release in the conscious rat. Eur J Pharmacol. 1990 Feb 20;177(1-2):107–110. doi: 10.1016/0014-2999(90)90558-n. [DOI] [PubMed] [Google Scholar]
  7. Chaouloff F., Jeanrenaud B. 5-HT1A and alpha-2 adrenergic receptors mediate the hyperglycemic and hypoinsulinemic effects of 8-hydroxy-2-(di-n-propylamino)tetralin in the conscious rat. J Pharmacol Exp Ther. 1987 Dec;243(3):1159–1166. [PubMed] [Google Scholar]
  8. Chaouloff F., Laude D., Baudrie V. Ganglionic transmission is a prerequisite for the adrenaline-releasing and hyperglycemic effects of 8-OH-DPAT. Eur J Pharmacol. 1990 Aug 21;185(1):11–18. doi: 10.1016/0014-2999(90)90205-k. [DOI] [PubMed] [Google Scholar]
  9. Cohen M. L., Fuller R. W., Kurz K. D. LY53857, a selective and potent serotonergic (5-HT2) receptor antagonist, does not lower blood pressure in the spontaneously hypertensive rat. J Pharmacol Exp Ther. 1983 Nov;227(2):327–332. [PubMed] [Google Scholar]
  10. Cohen M. L., Kurz K. D., Mason N. R., Fuller R. W., Marzoni G. P., Garbrecht W. L. Pharmacological activity of the isomers of LY53857, potent and selective 5-HT2 receptor antagonists. J Pharmacol Exp Ther. 1985 Nov;235(2):319–323. [PubMed] [Google Scholar]
  11. Connor H. E., Higgins G. A. Cardiovascular effects of 5-HT1A receptor agonists injected into the dorsal raphe nucleus of conscious rats. Eur J Pharmacol. 1990 Jun 21;182(1):63–72. doi: 10.1016/0014-2999(90)90493-p. [DOI] [PubMed] [Google Scholar]
  12. Dabiré H., Chaouche-Teyara K., Cherqui C., Fournier B., Schmitt H. DOI is a mixed agonist-antagonist at postjunctional 5-HT2 receptors in the pithed rat. Eur J Pharmacol. 1989 Oct 24;170(1-2):109–111. doi: 10.1016/0014-2999(89)90143-x. [DOI] [PubMed] [Google Scholar]
  13. Dalton D. W. The cardiovascular effects of centrally administered 5-hydroxytryptamine in the conscious normotensive and hypertensive rat. J Auton Pharmacol. 1986 Mar;6(1):67–75. doi: 10.1111/j.1474-8673.1986.tb00632.x. [DOI] [PubMed] [Google Scholar]
  14. Dedeoğlu A., Fisher L. A. Central nervous actions of serotonin and a serotonin1A receptor agonist: cardiovascular excitation at low doses. J Pharmacol Exp Ther. 1991 Apr;257(1):425–432. [PubMed] [Google Scholar]
  15. Doods H. N., Boddeke H. W., Kalkman H. O., Hoyer D., Mathy M. J., van Zwieten P. A. Central 5-HT1A receptors and the mechanism of the central hypotensive effect of (+)8-OH-DPAT, DP-5-CT, R28935, and urapidil. J Cardiovasc Pharmacol. 1988 Apr;11(4):432–437. doi: 10.1097/00005344-198804000-00008. [DOI] [PubMed] [Google Scholar]
  16. Dreteler G. H., Wouters W., Saxena P. R., Ramage A. G. Pressor effects following microinjection of 5-HT1A receptor agonists into the raphe obscurus of the anaesthetized rat. Br J Pharmacol. 1991 Feb;102(2):317–322. doi: 10.1111/j.1476-5381.1991.tb12172.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fozard J. R., Mir A. K., Middlemiss D. N. Cardiovascular response to 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) in the rat: site of action and pharmacological analysis. J Cardiovasc Pharmacol. 1987 Mar;9(3):328–347. doi: 10.1097/00005344-198703000-00010. [DOI] [PubMed] [Google Scholar]
  18. Fuller R. W., Kurz K. D., Mason N. R., Cohen M. L. Antagonism of a peripheral vascular but not an apparently central serotonergic response by xylamidine and BW 501C67. Eur J Pharmacol. 1986 Jun 5;125(1):71–77. doi: 10.1016/0014-2999(86)90084-1. [DOI] [PubMed] [Google Scholar]
  19. Gillis R. A., Hill K. J., Kirby J. S., Quest J. A., Hamosh P., Norman W. P., Kellar K. J. Effect of activation of central nervous system serotonin 1A receptors on cardiorespiratory function. J Pharmacol Exp Ther. 1989 Feb;248(2):851–857. [PubMed] [Google Scholar]
  20. Hartle D. K., Brody M. J. The angiotensin II pressor system of the rat forebrain. Circ Res. 1984 Apr;54(4):355–366. doi: 10.1161/01.res.54.4.355. [DOI] [PubMed] [Google Scholar]
  21. Holtman J. R., Jr, Anastasi N. C., Norman W. P., Dretchen K. L. Effect of electrical and chemical stimulation of the raphe obscurus on phrenic nerve activity in the cat. Brain Res. 1986 Jan 8;362(2):214–220. doi: 10.1016/0006-8993(86)90446-4. [DOI] [PubMed] [Google Scholar]
  22. Holtman J. R., Jr, Dick T. E., Berger A. J. Involvement of serotonin in the excitation of phrenic motoneurons evoked by stimulation of the raphe obscurus. J Neurosci. 1986 Apr;6(4):1185–1193. doi: 10.1523/JNEUROSCI.06-04-01185.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Inoue A., Buñag R. D. Sympathetic inhibition and vasopressin mediation during centrally induced responses to serotonin in rats. J Cardiovasc Pharmacol. 1989 Jun;13(6):902–907. doi: 10.1097/00005344-198906000-00013. [DOI] [PubMed] [Google Scholar]
  24. Iovino M., Steardo L. Vasopressin release to central and peripheral angiotensin II in rats with lesions of the subfornical organ. Brain Res. 1984 Nov 26;322(2):365–368. doi: 10.1016/0006-8993(84)90135-5. [DOI] [PubMed] [Google Scholar]
  25. Krstić M. K., Djurković D. Analysis of cardiovascular responses to central administration of 5-hydroxytryptamine in rats. Neuropharmacology. 1980 May;19(5):455–463. doi: 10.1016/0028-3908(80)90053-2. [DOI] [PubMed] [Google Scholar]
  26. Krstić M. K., Djurković D. Hypertension mediated by the activation of the rat brain 5-hydroxytryptamine receptor sites. Experientia. 1976 Sep 15;32(9):1187–1189. doi: 10.1007/BF01927618. [DOI] [PubMed] [Google Scholar]
  27. Lambert G. A., Friedman E., Buchweitz E., Gershon S. Involvement of 5-hydroxytryptamine in the central control of respiration, blood pressure and heart rate in the anaesthetized rat. Neuropharmacology. 1978 Oct;17(10):807–813. doi: 10.1016/0028-3908(78)90068-0. [DOI] [PubMed] [Google Scholar]
  28. Lambert G., Friedman E., Gershon S. Centrally-mediated carcdiovascular responses to 5-HT. Life Sci. 1975 Sep 15;17(6):915–919. doi: 10.1016/0024-3205(75)90443-9. [DOI] [PubMed] [Google Scholar]
  29. Mawson C., Whittington H. Evaluation of the peripheral and central antagonistic activities against 5-hydroxytryptamine of some new agents. Br J Pharmacol. 1970 May;39(1):223P–224P. [PMC free article] [PubMed] [Google Scholar]
  30. McCall R. B., Harris L. T. 5-HT2 receptor agonists increase spontaneous sympathetic nerve discharge. Eur J Pharmacol. 1988 Jun 22;151(1):113–116. doi: 10.1016/0014-2999(88)90698-x. [DOI] [PubMed] [Google Scholar]
  31. Middlemiss D. N., Fozard J. R. 8-Hydroxy-2-(di-n-propylamino)-tetralin discriminates between subtypes of the 5-HT1 recognition site. Eur J Pharmacol. 1983 May 20;90(1):151–153. doi: 10.1016/0014-2999(83)90230-3. [DOI] [PubMed] [Google Scholar]
  32. Mironneau J., Arnaudeau S., Mironneau C. Fenoverine inhibition of calcium channel currents in single smooth muscle cells from rat portal vein and myometrium. Br J Pharmacol. 1991 Sep;104(1):65–70. doi: 10.1111/j.1476-5381.1991.tb12386.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Nosjean A., Guyenet P. G. Role of ventrolateral medulla in sympatholytic effect of 8-OHDPAT in rats. Am J Physiol. 1991 Mar;260(3 Pt 2):R600–R609. doi: 10.1152/ajpregu.1991.260.3.R600. [DOI] [PubMed] [Google Scholar]
  34. Pérgola P. E., Alper R. H. Effects of central serotonin on autonomic control of heart rate in intact and baroreceptor deficient rats. Brain Res. 1992 Jun 12;582(2):215–220. doi: 10.1016/0006-8993(92)90135-v. [DOI] [PubMed] [Google Scholar]
  35. Pérgola P. E., Alper R. H. Vasopressin and autonomic mechanisms mediate cardiovascular actions of central serotonin. Am J Physiol. 1991 Jun;260(6 Pt 2):R1188–R1193. doi: 10.1152/ajpregu.1991.260.6.R1188. [DOI] [PubMed] [Google Scholar]
  36. RUBIN B., PIALA J. J., BURKE J. C., CRAVER B. N. A NEW, POTENT AND SPECIFIC SEROTONIN INHIBITOR, (SQ 10,643) 2'-(3-DIMETHYLAMINOPROPYLTHIO) CINNAMANILIDE HYDROCHLORIDE: ANTISEROTONIN ACTIVITY ON UTERUS AND ON GASTROINTESTINAL, VASCULAR, AND RESPIRATORY SYSTEMS OF ANIMALS. Arch Int Pharmacodyn Ther. 1964 Nov 1;152:132–143. [PubMed] [Google Scholar]
  37. Ramage A. G. A comparison of the effects of doxazosin and alfuzosin with those of urapidil on preganglionic sympathetic nerve activity in anaesthetised cats. Eur J Pharmacol. 1986 Oct 7;129(3):307–314. doi: 10.1016/0014-2999(86)90440-1. [DOI] [PubMed] [Google Scholar]
  38. Ramage A. G. Influence of 5-HT1A receptor agonists on sympathetic and parasympathetic nerve activity. J Cardiovasc Pharmacol. 1990;15 (Suppl 7):S75–S85. [PubMed] [Google Scholar]
  39. Ramage A. G. The effects of ketanserin, methysergide and LY 53857 on sympathetic nerve activity. Eur J Pharmacol. 1985 Jul 31;113(3):295–303. doi: 10.1016/0014-2999(85)90076-7. [DOI] [PubMed] [Google Scholar]
  40. Ramage A. G., Wilkinson S. J. Evidence that different regional sympathetic outflows vary in their sensitivity to the sympathoinhibitory actions of putative 5-HT1A and alpha 2-adrenoceptor agonists in anaesthetized cats. Br J Pharmacol. 1989 Dec;98(4):1157–1164. doi: 10.1111/j.1476-5381.1989.tb12660.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Schoeffter P., Hoyer D. Centrally acting hypotensive agents with affinity for 5-HT1A binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocampus. Br J Pharmacol. 1988 Nov;95(3):975–985. doi: 10.1111/j.1476-5381.1988.tb11728.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Shepheard S. L., Jordan D., Ramage A. G. Investigation of the effects of IVth ventricular administration of the 5-HT2 agonist, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), on autonomic outflow in the anaesthetized cat. Br J Pharmacol. 1991 Oct;104(2):367–372. doi: 10.1111/j.1476-5381.1991.tb12437.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Smits J. F., Struyker-Boudier H. A. Intrahypothalamic serotonin and cardiovascular control in rats. Brain Res. 1976 Jul 30;111(2):422–427. doi: 10.1016/0006-8993(76)90788-5. [DOI] [PubMed] [Google Scholar]
  44. Sporton S. C., Shepheard S. L., Jordan D., Ramage A. G. Microinjections of 5-HT1A agonists into the dorsal motor vagal nucleus produce a bradycardia in the atenolol-pretreated anaesthetized rat. Br J Pharmacol. 1991 Oct;104(2):466–470. doi: 10.1111/j.1476-5381.1991.tb12452.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Steardo L., Iovino M. Vasopressin release after enhanced serotonergic transmission is not due to activation of the peripheral renin-angiotensin system. Brain Res. 1986 Sep 10;382(1):145–148. doi: 10.1016/0006-8993(86)90122-8. [DOI] [PubMed] [Google Scholar]
  46. Sukamoto T., Yamamoto T., Watanabe S., Ueki S. Cardiovascular responses to centrally administered serotonin in conscious normotensive and spontaneously hypertensive rats. Eur J Pharmacol. 1984 Apr 20;100(2):173–179. doi: 10.1016/0014-2999(84)90219-x. [DOI] [PubMed] [Google Scholar]
  47. Valenta B., Singer E. A. Hypotensive effects of 8-hydroxy-2-(di-n-propylamino)tetralin and 5-methylurapidil following stereotaxic microinjection into the ventral medulla of the rat. Br J Pharmacol. 1990 Apr;99(4):713–716. doi: 10.1111/j.1476-5381.1990.tb12994.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Van de Kar L. D. Neuroendocrine pharmacology of serotonergic (5-HT) neurons. Annu Rev Pharmacol Toxicol. 1991;31:289–320. doi: 10.1146/annurev.pa.31.040191.001445. [DOI] [PubMed] [Google Scholar]
  49. Vayssettes-Courchay C., Bouysset F., Verbeuren T. J., Laubie M., Schmitt H. Quipazine-induced hypertension in anaesthetized cats is mediated by central and peripheral 5-HT2 receptors: role of the ventrolateral pressor area. Eur J Pharmacol. 1991 Jan 17;192(3):389–395. doi: 10.1016/0014-2999(91)90230-n. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES